Canine Inflammatory Bowel Disease Study Guide

Overview and Clinical Importance

Inflammatory bowel disease (IBD) is a collective term for a group of chronic, idiopathic inflammatory disorders affecting the gastrointestinal tract of dogs. These conditions are characterized by persistent or recurrent gastrointestinal signs lasting more than 3 weeks, histologic evidence of mucosal inflammation, and exclusion of other identifiable causes. IBD represents one of the most common causes of chronic vomiting and diarrhea in dogs and is frequently tested on the NAVLE.

The pathogenesis involves complex interactions between genetic susceptibility, the intestinal microbiome, dietary antigens, and immune dysregulation. Current understanding suggests IBD results from loss of immunological tolerance to normal luminal antigens in genetically predisposed individuals.

Classification of Chronic Enteropathies

Modern terminology classifies canine chronic enteropathies (CE) based on response to treatment rather than solely on histopathology. This recognizes that histologic findings alone cannot reliably distinguish between different forms of CE.

Chronic Enteropathy Classification by Treatment Response

Histopathologic Classification

IBD is classified by the predominant inflammatory cell type infiltrating the lamina propria. The WSAVA Gastrointestinal Standardization Group has established histopathologic criteria for grading inflammation as normal, mild, moderate, or marked.

Breed Predispositions and Special Syndromes

Several breeds have recognized predispositions to specific forms of IBD, suggesting a genetic component. Mean age at diagnosis is approximately 6.3 years, though dogs as young as 8 months can be affected.

Clinical Presentation

Clinical signs of IBD vary based on the anatomic location and severity of inflammation. Signs are typically chronic (greater than 3 weeks), intermittent or cyclic, and progressive.

Clinical Signs by Anatomic Location

Physical Examination Findings: Often unremarkable in mild to moderate cases. Potential findings include:

• Poor body condition, muscle wasting (cachexia) in severe cases
• Thickened intestinal loops on abdominal palpation
• Abdominal discomfort or pain
• Ascites, peripheral edema (if severe hypoalbuminemia with PLE)
• Dehydration in severe cases with ongoing losses

Diagnostic Approach

IBD is a diagnosis of exclusion. All other potential causes of chronic GI signs must be ruled out. The WSAVA criteria for IBD diagnosis require:

• Persistent GI signs for greater than 3 weeks
• Failure to respond to symptomatic therapy (antiparasitics, antibiotics, GI protectants)
• Exclusion of other causes through diagnostic evaluation
• Histopathologic evidence of intestinal inflammation

Laboratory Findings

Diagnostic Imaging

Abdominal Radiography

Radiographs are typically nonspecific in IBD. Primary utility is to rule out foreign bodies, masses, or obstruction.

Abdominal Ultrasonography

Important: IBD CANNOT be diagnosed by ultrasound alone. However, ultrasound is valuable for ruling out mass lesions, assessing wall thickness, evaluating lymph nodes, and guiding biopsy decisions.

Endoscopy and Histopathology

Intestinal biopsy with histopathologic examination is required for definitive diagnosis. Biopsies can be obtained via endoscopy (mucosal samples) or surgical laparotomy (full-thickness samples).

Endoscopic Findings in IBD

• Mucosal erythema (redness)
• Increased friability (bleeds easily with contact)
• Increased granularity (cobblestone appearance)
• Mucosal erosions or ulceration
• White speckling (indicates lymphangiectasia)

Clinical Scoring Indices

Two validated scoring systems assess disease severity and monitor treatment response:

Canine IBD Activity Index (CIBDAI)

CIBDAI Interpretation: 0-3 = Clinically insignificant; 4-5 = Mild IBD; 6-8 = Moderate IBD; 9 or greater = Severe IBD

Treatment

Treatment involves a stepwise approach, starting with less aggressive interventions. The goal is to achieve clinical remission with the lowest effective dose of medication.

Stepwise Treatment Approach

Step 1 - Empirical Deworming: Fenbendazole 50 mg/kg PO daily for 5 days

Step 2 - Diet Trial: Novel protein OR hydrolyzed protein diet exclusively for 2-4 weeks

Step 3 - Antibiotic Trial: Metronidazole or tylosin for 2-4 weeks if no response to diet

Step 4 - Immunosuppression: Corticosteroids with or without additional immunosuppressants

Step 5 - Cobalamin Supplementation: If hypocobalaminemic: 250-1500 mcg SC weekly OR PO daily

Pharmacologic Treatment

Prognosis and Prognostic Factors

Prognosis is variable. IBD is typically controlled rather than cured, with relapses common.

Exam Focus: The two most important negative prognostic indicators are HYPOALBUMINEMIA and HYPOCOBALAMINEMIA. Approximately 50% of dogs respond to diet alone, about 50% require immunosuppression, and approximately 10-15% fail to respond to any therapy.